Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Rawrasauruson Aug 18, 2021 2:14pm
156 Views
Post# 33724487

RE:Not a Scientist but...

RE:Not a Scientist but...

Long term, I would be incredibly surprised if this kills the drug. It's just not clinically significant. Even at 5x increase in enzymes, that's still lower than Tylenol and even Naproxen. Naproxen alone can lead to elevations  in adverse events around 500+ whereas 5x only puts us in the 250 range.

 

Best guesses are still NAFLD or genetic variability of the patient populations rather than something inherent to the drug. It appears we can go lower though, so even if it is the drug that is inhibiting a certain pathway for clearance, that just changes our dosing schedule to achieve stable serum levels. Remember, the goal here is long term oa 1x daily treatment. If we can prove gi/lte safety and pain relief over the long term, we are golden even if the drug takes a week or two to reach serum stability.

<< Previous
Bullboard Posts
Next >>